We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




MDx Platform Offers Largest Variety of Leukemia-Related Diagnostic Tests for Early Detection

By LabMedica International staff writers
Posted on 26 Apr 2023
Print article
Image: Lena Q51 is part of the LENA Molecular Dx Leukemia Platform comprising 12 molecular diagnostic tests (Photo courtesy of Alercell)
Image: Lena Q51 is part of the LENA Molecular Dx Leukemia Platform comprising 12 molecular diagnostic tests (Photo courtesy of Alercell)

Leukemia, also known as blood cancer, is a malignant disease affecting the blood system. It is the most common cancer in children under 15, accounting for roughly one-third of all childhood tumors. The number of leukemia cases is rising annually. Traditional leukemia detection involves blood tests followed by a bone marrow biopsy, which can be time-consuming and subjective due to the reliance on human interpretation of cytology. This process typically takes between 3 to 6 weeks. Now, a new molecular leukemia diagnostic platform offers 12 molecular diagnostic tests specialized in leukemia early diagnosis, treatment guidance and MRD (Minimal residual disease) monitoring.

Alercell, Inc. (Bozeman, MT, USA) has unveiled the LENA Molecular Dx Leukemia Platform, a set of 12 next-generation DNA sequencing tests that can be processed using a standard qPCR machine. The tests have a user-friendly protocol, are compatible with standard qPCR equipment, and are designed to fit into the workflow of a clinical microbiology lab. These tests utilize industry-standard PCR and DNA purification technology.

Some of the tests are designated for Research Use Only (RUO), such as the RUO LENA Q51 introduced by Alercell in January 2023. LENA Q51 is the most comprehensive test, encompassing all other tests, although the company aims to make all tests accessible through the platform. Alercell plans to add new tests to cover all aspects of leukemia testing, providing practitioners with a single location for every available test. By offering these tests at competitive prices, Alercell seeks to increase access for more patients, hospitals, and cancer centers, leading to early detection and prompt treatment of leukemia.

“This new platform was designed to create a one-stop-shop for Leukemia, where practitioners do not need to look for many different manufacturers,” said Frederic Scheer, chairman & CEO of Alercell. “Our goal at Alercell is to become the reference for Leukemia and offer a complete solution. Our R&D team is working on additional tests to add to the platform in the months and years to come. I believe that several of the tests designed to improve patient outcomes will assist practitioners in selecting the appropriate therapeutics for Leukemia patients. Early detection drastically enhances the survival rates of patients and Alercell is focusing on making sure that we give every patient the best chances of survival.”

Related Links:
Alercell, Inc. 

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Silver Supplier
Immunoblots for Myositis Diagnostics
EUROLINE Myositis Profiles

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Technology

view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.